

ASX RELEASE

9th August 2018

US Media Coverage : Mr. Christopher Collins

Innate Immunotherapeutics Limited (the "Company") has been made aware of overnight media reports that Mr Christopher Collins, a former director of the Company, has been indicted by US federal prosecutors for insider trading.

The Company wishes to advise that it has cooperated fully with requests for information made to it by the U.S. Securities and Exchange Commission (SEC). The Company and its directors/officers (excepting Mr. Collins) are not under investigation. The Company considers the ongoing investigation to be a private matter to Mr. Collins.

The US media has inaccurately reported that Mr Collins and colleagues were the beneficiaries of share issuances in the Company on privileged terms. Mr Collins (and colleagues) have only ever participated in shareholder-approved share placements or "rights issues" of shares in the Company. As is typical for a rights issue in Australia, the issue price was at a discount to market and fully disclosed as such.

Mr Collins was retired as a director of Innate Immunotherapeutics in early May of this year. Mr Collins is no longer involved with the governance of the Company.

- End -

Company Contact:

Andrew Cooke
Non-Executive Director
Company Secretary
Email: andrew@innateimmuno.com

For personal use only